Immunotherapy Breakthrough: Immune Checkpoint Inhibitors in Cancer Treatment
DOI:
https://doi.org/10.54097/eqy95j75Keywords:
Immune checkpoint inhibitors; cancer immunotherapy; PD-1/PD-L1; CTLA-4.Abstract
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, offering new possibilities for patients with various malignancies. This review examines the molecular mechanisms of immune checkpoints (ICs), particularly the PD-1/PD-L1 and CTLA-4 pathways, and their roles in tumor immune evasion. Major ICIs, including anti-PD-1/PD-L1 and anti-CTLA-4 drugs, are discussed, with emphasis on their effectiveness in treating both solid and hematological cancers. The review also explores combination treatment strategies that aim to improve therapeutic outcomes. Despite considerable progress, challenges such as drug resistance and immune-related adverse events (irAEs) remain. These issues are addressed, alongside an exploration of future directions, including novel ICs such as LAG-3, TIM-3, and TIGIT. The conclusion highlights the significant impact of ICIs on cancer immunotherapy while acknowledging the need for continued research to overcome existing challenges. Future efforts should focus on developing more targeted therapies, optimizing combination treatments, and identifying biomarkers to enhance efficacy and safety, ultimately advancing the field of cancer immunotherapy.
Downloads
References
[1] Pardoll D M. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 2012, 12(4): 252–264. DOI: https://doi.org/10.1038/nrc3239
[2] Brahmer J R, Tykodi S S, Chow L Q M, et al. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer. New England Journal of Medicine, 2012, 366(26): 2455–2465. DOI: https://doi.org/10.1056/NEJMoa1200694
[3] Seton-Rogers S. Cooperative crosstalk. Nature Reviews Cancer, 2015, 15(4): 198–198. DOI: https://doi.org/10.1038/nrc3937
[4] Ribas A, Wolchok J D. Cancer immunotherapy using checkpoint blockade. Science, 2018, 359(6382): 1350–1355. DOI: https://doi.org/10.1126/science.aar4060
[5] Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 2015, 373(1): 23–34. DOI: https://doi.org/10.1056/NEJMoa1504030
[6] Reck M, Rodríguez-Abreu D, Robinson A G, et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2016, 375(19): 1823–1833. DOI: https://doi.org/10.1056/NEJMoa1606774
[7] Robert C, Schachter J, Long G V, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2015, 372(26): 2521–2532. DOI: https://doi.org/10.1056/NEJMoa1503093
[8] Hargadon K M, Johnson C E, Williams C J. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. International Immunopharmacology, 2018, 62: 29–39. DOI: https://doi.org/10.1016/j.intimp.2018.06.001
[9] Michot J M, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. European Journal of Cancer, 2016, 54: 139–148. DOI: https://doi.org/10.1016/j.ejca.2015.11.016
[10] Vonderheide R H, Glennie M J. Agonistic CD40 Antibodies and Cancer Therapy. Clinical Cancer Research, 2013, 19(5): 1035–1043. DOI: https://doi.org/10.1158/1078-0432.CCR-12-2064
[11] Brahmer J, Reckamp K L, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 373(2): 123–135. DOI: https://doi.org/10.1056/NEJMoa1504627
[12] Antonia S J, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 377(20): 1919–1929. DOI: https://doi.org/10.1056/NEJMoa1709937
[13] Hodi F S, O’Day S J, McDermott D F, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 2010, 363(8): 711–723. DOI: https://doi.org/10.1056/NEJMoa1003466
[14] Postow M A, Sidlow R, Hellmann M D. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. D.L. Longo. New England Journal of Medicine, 2018, 378(2): 158–168. DOI: https://doi.org/10.1056/NEJMra1703481
[15] Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2019, 381(16): 1535–1546. DOI: https://doi.org/10.1056/NEJMoa1910836
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
